NCT06072118View on ClinicalTrials.gov

Adrenomedullin for CADASIL

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 6, 2022

Primary Completion Date

January 23, 2023

Study Completion Date

June 12, 2023

Conditions
Cadasil
Interventions
DRUG

Adrenomedullin

Dosing at 15 ng/kg/min for 8 hours is continued for 14 days.

Trial Locations (1)

564-8565

National Cerebral and Cardiovascular Center, Suita

All Listed Sponsors
lead

National Cerebral and Cardiovascular Center, Japan

OTHER

NCT06072118 - Adrenomedullin for CADASIL | Biotech Hunter | Biotech Hunter